SAREPTA THERAPEUTICS, INC. Accrued Income Taxes
SAREPTA THERAPEUTICS, INC. (SRPT) had Accrued Income Taxes of $9.31 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:AccruedIncomeTaxes · last filed 2026-08-05
- 2026-06-30: Accrued Income Taxes $9.31M.
- 2026-03-31: Accrued Income Taxes $13.79M.
- 2025-12-31: Accrued Income Taxes $4.75M.
- 2025-09-30: Accrued Income Taxes $9.09M.
| Period end | Accrued Income Taxes |
|---|---|
| 2026-06-30 | $9.31M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $13.79M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $4.75M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $9.09M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $18.73M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $79.86M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $17.39M 10-K · filed 2026-03-02 |
| 2024-09-30 | $14.70M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $18.19M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $18.29M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $13.77M 10-K · filed 2025-02-28 |
| 2023-09-30 | $24.68M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $20.82M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $16.09M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $12.52M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.09M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $2.48M 10-Q · filed 2022-08-02 |
| 2021-12-31 | $216.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |